Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer

Wang, Xiaochuan; Zhang, Yi; Sun, Liangqi; Wang, Shuaiping; Nie, Jing; Zhao, Wenqing; Zheng, Guobao

doi:10.1002/jcla.22565

Cited by 25 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our current study, among the lung cancer patients who underwent testing for EGFR mutations, 49.10% had mutations in the younger group, and 44.81% had mutations in the older group; the difference was not significant, which was consistent with a recent study in Chinese patients 46 . CEA is one of the most widely used tumour markers, and elevated CEA expression is often observed in patients with lung cancer, especially those with adenocarcinoma 49 , 50 . SCC has been confirmed to be closely related to the prognosis of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China

Shi

Liang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To explore the epidemiological characteristics and prognosis of lung cancer in patients aged under 45 years old in northern China. The population-based database about lung cancer cases aged under 45y selected form the Hebei Provincial Cancer Registry Center from 2010–2015. Mortality data of young death from 1973 to 1975, 1990 to 1992, and 2004 to 2005 were extracted from the national retrospective survey of death. Mortality rates were calculated by the mortality database above in this analysis. Consecutive, 954 non-selected younger patients (< 45 years) and 2261 selected older patients (≥ 45 years) with pathologically diagnosed lung cancer treated at the Fourth Hospital of Hebei Medical University were included as the hospital-based database. Epidemiological, treatment outcomes and prognosis status from 2010 to 2017 were documented. A comparison with younger and older patients was also made. Multivariate analysis with young lung cancer patients was calculated by Cox regression model. The younger lung cancer mortality rate tended to slightly increase in Hebei Province, from 1.04 per100 000 in 1973 to 2.01 per 100 000 in 2015, but the PDR tended to decrease over the last 40 years. There were 954 younger and 2261 older lung cancer patients included in the hospital-based database. The proportions of patients who were female (50.84% vs 34.85%), family history of cancer (12.37% vs 6.32%), advanced stage at diagnosis (65.46% vs 60.77%) and adenocarcinoma (65.27% vs 61.11%) were relatively higher in the younger group than in the older group. The median OS were 23.0 months and 27.0 months between younger and older, the OS difference existed between the two groups (P = 0.001). In the younger patients, Cox regression showed that a family history of cancer, symptoms at diagnosis, pathology, stage at diagnosis and surgery were confirmed as independent factors affecting the prognosis. Mortality rates among younger lung cancer patients showed an increasing trend in northern China. The younger account for small but have unique characteristics, with higher proportions of female, family history of cancer, adenocarcinoma and advanced stages than the older group and had a trend of worse OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China

Shi

Liang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In this study, the mean value in lung cancer was 18.49±45.97 (Table 1), but Huaiqian Dou et al [10] reported that the mean in lung cancer was 9.34±13.67. In contrast, Xiaochuan Wang et al [32] reported that it was 28.39±51.91. These differences might be caused by a sampling error, detection kit choice, and instrument differences.…”

Section: Discussionmentioning

confidence: 89%

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Shen

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCA242 is a classic biomarker used for diagnosing digestive tract tumors, especially pancreatic cancer. However, CA242 serum levels in some tumor patients and what might influence these levels remain unknown or uncertain. This study aimed to reveal the pancancer landscape of serum CA242 levels and identify some influencing factors.MethodsIn the current study, serum CA242 levels and clinical information, including clinical stage and metastatic status, were collected from 37,493 patients with 35 different types of neoplastic disease, and CA242 values were also obtained for 880 healthy controls.ResultsSerum CA242 levels in patients with one of 21 different cancers were significantly higher than those in healthy controls and had diagnostic value in 9 tumors (AUC>0.7, P<0.05); serum CA242 levels were increased across all malignant digestive tract tumors. Compared to patients without metastasis, cancer patients with one of 15 kinds of cancer with lymph node metastasis and distant metastasis showed elevated CA242 levels. Moreover, CA242 was helpful in distinguishing the clinical stage and metastatic status in 6 cancers. In addition, the presence of multiple metastases and liver metastasis might result in increased CA242 levels.ConclusionsOverall, CA242 can not only serve as a diagnostic biomarker for malignant tumors in the digestive system but also predict the progression, stage, and metastasis of many other tumors that have not received clinical attention.

show abstract

“…NSE is a type of tumor markers of SCLC, [31] and related studies have shown that plasma Fbg often increases obviously in SCLC patients. [7,24] The mechanisms activating coagulation and fibrinolysis in SCLC patients and NSCLC patients are different.…”

Section: Discussionmentioning

confidence: 99%

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Bian¹,

Shi

Qi³

et al. 2019

Medicine

View full text Add to dashboard Cite

Numerous studies have shown that the blood of cancer patients are generally in hypercoagulable statement. The aim of the present research is to study the relationships of plasma fibrinogen (Fbg) levels with clinicopathological stages (CS) and tumor markers of non-small cell lung cancer (NSCLC). Baseline information, plasma Fbg levels, CS, and expression level of tumor markers were collected from medical records retrospectively. Unitary linear regression was used to analyze the relationships between continuous variables and Fbg, and multiple linear regression was used to analyze the relationships between categorical variables and Fbg. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (Version 4) for NSCLC were adopted to evaluate CS. A total of 652 NSCLC patients were included. Compared with the females, male patients had higher mean plasma Fbg levels ( P < .001). The later the N stages ( P = .002), M stages ( P = .002), and CS ( P = .001) were, the higher the average plasma Fbg levels were. The levels of squamous cell carcinoma antigen ( P = .001), carbohydrate antigen 125 ( P = .041), and neuron-specific enolase ( P < .001) were positively correlated with plasma Fbg concentration. The plasma level of Fbg in lung adenocarcinoma patients ( P < .001) was the lowest, while that of lung squamous cell carcinoma patients ( P < .001) was the highest in NSCLC patients. The plasma Fbg concentration is related to gender, CS, and tumor markers in patients with NSCLC.

show abstract

Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer

Abstract: The C-12 multiple tumor protein-chip detective system has acceptable sensitivity in the diagnostic of lung cancer.

Cited by 25 publications

References 21 publications

Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China

Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Contact Info

Product

Resources

About